Prospective validation of the Barcelona Clinic Liver Cancer staging system

scientific article published on 24 January 2006

Prospective validation of the Barcelona Clinic Liver Cancer staging system is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JHEP.2005.12.015
P698PubMed publication ID16488051

P50authorUmberto CilloQ43274404
Giacomo ZanusQ95630401
Davide Francesco D'AmicoQ117812114
P2093author name stringAlessandro Vitale
Francesco Grigoletto
Fabio Farinati
Daniele Neri
Patrizia Boccagni
Alessio Bridda
Alberto Brolese
Francesco Antonio Ciarleglio
Francesco D'Amico
Nela Srsen
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectliver cancerQ623031
BarcelonaQ1492
P304page(s)723-731
P577publication date2006-01-24
P1433published inJournal of HepatologyQ15724402
P1476titleProspective validation of the Barcelona Clinic Liver Cancer staging system
P478volume44

Reverse relations

cites work (P2860)
Q5323312118F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.
Q41601109A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression
Q92424376A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma
Q33966175A conceptual proposal for staging ductal cholangiocarcinoma
Q33916361A multidisciplinary approach to the management of hepatocellular carcinoma
Q84534500A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort
Q89516462A panel of five plasma proteins for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma in individuals at risk
Q53313895A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function.
Q39702687Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy
Q36836103Advanced hepatocellular carcinoma: which staging systems best predict prognosis?
Q40707188Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma.
Q53379427Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
Q89927855Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma
Q35833112Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center
Q35780838Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival
Q53220944Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.
Q39692205Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified?
Q35594282Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging
Q33805894Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective
Q84388181Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study
Q33572657Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort
Q36193809Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?
Q36970515Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma
Q26766707Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma
Q92979177Challenges of transarterial therapy for hepatocellular carcinoma in patients with chronic kidney disease
Q37289933Clinical implications of basic research in hepatocellular carcinoma
Q88733788Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy
Q42553272Comparative performances of staging systems for early hepatocellular carcinoma
Q37396794Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization
Q35113002Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt
Q52658496Comparison and validation of the prognostic value of preoperative systemic immune cells in hepatocellular carcinoma after curative hepatectomy.
Q53557508Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Q36741673Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience
Q34847211Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization
Q34776673Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis.
Q35094309Comparison of staging systems of hepatocellular carcinoma
Q57763504Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score
Q58598133Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review
Q36429818Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients
Q37072518Current management of advanced hepatocellular carcinoma
Q84121761Current management of hepatocellular cancer
Q87604943Current management of hepatocellular carcinoma
Q43093342Current management strategy of hepatocellular carcinoma
Q36360832Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma
Q44195991DNA methylation profiling identifies EYA4 gene as a prognostic molecular marker in hepatocellular carcinoma
Q36634582Decreased expression of Sushi Domain Containing 2 correlates to progressive features in patients with hepatocellular carcinoma
Q37798817Developing better treatments in hepatocellular carcinoma
Q44220846Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting
Q40020398Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre
Q59150373Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Q38763789Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals
Q33403106Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study
Q53450730Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Q39697040Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue
Q49386865Expression of cluster of differentiation 151 prior to and following transcatheter arterial chemoembolization therapy in patients with hepatocellular carcinoma and its association with clinicopathological characteristics
Q36375463FRZB up-regulated in hepatocellular carcinoma bone metastasis
Q36589471Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma
Q47140323Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study
Q92837846Genetic heterogeneity in hepatocellular carcinoma and paired bone metastasis revealed by next-generation sequencing
Q57492763HBV-DNA Load-Related Peritumoral Inflammation and ALBI Scores Predict HBV Associated Hepatocellular Carcinoma Prognosis after Curative Resection
Q34401855HCC surveillance results in earlier HCC detection: results from an Indian cohort
Q38762094HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival.
Q38460881Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis
Q51550710Hepatic resection for "BCLC stage A" hepatocellular carcinoma. The prognostic role of alpha-fetoprotein.
Q41315716Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System
Q36487795Hepatocellular Carcinoma Related to Schistosoma mansoni Infection: Case Series and Literature Review
Q35818322Hepatocellular Carcinoma Without Cirrhosis Presenting With Hypercalcemia: Case Report and Literature Review.
Q26767217Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective
Q55312644Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization.
Q48268747Hepatocellular Carcinoma: Surgical Management and Evolving Therapies
Q26783881Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols
Q37863539Hepatocellular carcinoma: MR staging and therapeutic decisions.
Q54988303High expression of miR-21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma.
Q38984450In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
Q48034232Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma
Q36327007Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101
Q51918787Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria.
Q64068788Is there a sex difference in postoperative prognosis of hepatocellular carcinoma?
Q50890846Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
Q64984085Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma.
Q26748756Liver resection for intermediate hepatocellular carcinoma
Q47601267Liver resection: a regional hospital experience
Q24658550Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
Q50100582Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma
Q34662021Long-term results of liver transplantation for hepatocellular carcinoma: an update of the University of Padova experience
Q58563301Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection
Q38615117Major Liver Resection for Large and Locally Advanced Hepatocellular Carcinoma
Q28258769Management of HCC
Q35771842Management of Hepatocellular Carcinoma: Current Status and Future Directions
Q24186856Management of people with early or very early stage hepatocellular carcinoma: a network meta-analysis
Q34681207Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
Q24186892Management of people with intermediate-stage hepatocellular carcinoma: a network meta-analysis
Q38747707Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.
Q42373841Mesoporous composite nanoparticles for dual-modality ultrasound/magnetic resonance imaging and synergistic chemo-/thermotherapy against deep tumors
Q34017735Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies
Q38935553Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration
Q37384682Multimodal approaches to the treatment of hepatocellular carcinoma
Q35469188Multimodal treatment of unresectable hepatocellular carcinoma to achieve complete response results in improved survival
Q38904263New concepts in embolotherapy of HCC.
Q48328889New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Q49901774Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
Q48741048Novel treatment strategy for advanced hepatocellular carcinoma: combination of conventional transcatheter arterial chemoembolization and modified method with portal vein occlusion for cases with arterioportal shunt: a preliminary study
Q90678432Ontology-Based Approach for Liver Cancer Diagnosis and Treatment
Q36069902Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study
Q90288434Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification
Q35792080Perineural invasion: a potential reason of hepatocellular carcinoma bone metastasis
Q42148721Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma.
Q49637785Prediction of long-term survival rates in patients undergoing curative resection for solitary hepatocellular carcinoma
Q42129377Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma
Q30432108Pretreatment assessment of hepatocellular carcinoma: expert consensus statement
Q34061430Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems
Q58283723Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages
Q35114970Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort.
Q36194925Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma
Q38216004Prognostic factors for hepatocellular carcinoma recurrence
Q37263149Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
Q37235913Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis
Q92308889Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma
Q51731281Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population.
Q45283698Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials
Q37012028Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience
Q36009475Reduced red blood cell count predicts poor survival after surgery in patients with primary liver cancer.
Q37338042Relationship between microvessel count and post-hepatectomy survival in patients with hepatocellular carcinoma
Q60936594Risk factors for liver Cancer in HIV endemic areas of Western Kenya
Q83186403Risk factors of early re-bleeding and mortality in patients with ruptured gastric varices and concomitant hepatocellular carcinoma
Q35738710Role functioning is associated with survival in patients with hepatocellular carcinoma
Q26851627Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma
Q53622404Safety and long-term outcomes of anatomic left hepatic trisectionectomy for intermediate and advanced hepatocellular carcinoma.
Q37169718Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score
Q36163425Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma
Q91638397Serum choline is associated with hepatocellular carcinoma survival: a prospective cohort study
Q33773415Staging of biliary tract and primary liver tumors
Q38408876Staging systems for hepatocellular carcinoma: Current status and future perspectives
Q38207014Staging systems of hepatocellular carcinoma: a review of literature
Q38661482State of the ablation nation: a review of ablative therapies for cure in the treatment of hepatocellular carcinoma
Q38948642Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database.
Q58576483Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status
Q58576456Surgical Resection Versus Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis
Q83609995Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging
Q64885102Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification?
Q36192647Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B.
Q50535030Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
Q55505579Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence.
Q38201654TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications
Q37606028The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy
Q38217657The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review.
Q33365826The impact of new data in the treatment of advanced hepatocellular carcinoma
Q35234037The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus
Q40136684Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma
Q41985384Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India
Q26784223Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system
Q59135179Transcatheter arterial chemoembolization monotherapy vs combined transcatheter arterial chemoembolization–percutaneous microwave coagulation therapy for massive hepatocellular carcinoma (≥10 cm)
Q38549768Treatment of Liver Cancer
Q30637327Unresectable hepatocellular carcinoma treated with transarterial chemoembolization: clinical data from a single teaching hospital
Q34571160Updates in the management of hepatocellular carcinoma
Q89767591Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma
Q26743666Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments
Q36001102Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study
Q53164616Validation of an extension of the international non-invasive criteria for the diagnosis of hepatocellular carcinoma to the characterization of macroscopic portal vein thrombosis.
Q51828236Validation of the BCLC prognostic system in surgical hepatocellular cancer patients.
Q47843414When to perform hepatic resection for intermediate-stage hepatocellular carcinoma
Q36326015Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma

Search more.